Reto Guler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5695238/publications.pdf

Version: 2024-02-01

50 papers

4,918 citations

172457 29 h-index 50 g-index

55 all docs 55 docs citations

55 times ranked 10271 citing authors

#	Article	IF	CITATIONS
1	Intranasally administered S-MGB-364 displays antitubercular activity and modulates the host immune response to <i>Mycobacterium tuberculosis</i> infection. Journal of Antimicrobial Chemotherapy, 2022, 77, 1061-1071.	3.0	5
2	Deletion of N-acetylmuramyl-L-alanine amidases alters the host immune response to <i>Mycobacterium tuberculosis</i> infection. Virulence, 2021, 12, 1227-1238.	4.4	3
3	MIREyA: a computational approach to detect miRNA-directed gene activation. F1000Research, 2021, 10, 249.	1.6	1
4	Evaluation of Berberine as an Adjunct to TB Treatment. Frontiers in Immunology, 2021, 12, 656419.	4.8	8
5	Targeting Molecular Inflammatory Pathways in Granuloma as Host-Directed Therapies for Tuberculosis. Frontiers in Immunology, 2021, 12, 733853.	4.8	20
6	IL-4i1 Regulation of Immune Protection During <i>Mycobacterium tuberculosis</i> Infection. Journal of Infectious Diseases, 2021, 224, 2170-2180.	4.0	3
7	The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty?. Cellular and Molecular Life Sciences, 2020, 77, 1497-1509.	5.4	48
8	Functional annotation of human long noncoding RNAs via molecular phenotyping. Genome Research, 2020, 30, 1060-1072.	5.5	109
9	Protocol for systematic review and meta-analysis: impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases. BMJ Open, 2020, 10, e039034.	1.9	1
10	Toward Preparing a Knowledge Base to Explore Potential Drugs and Biomedical Entities Related to COVID-19: Automated Computational Approach. JMIR Medical Informatics, 2020, 8, e21648.	2.6	9
11	Transcriptionally induced enhancers in the macrophage immune response to Mycobacterium tuberculosis infection. BMC Genomics, 2019, 20, 71.	2.8	16
12	Differential Targeting of c-Maf, Bach-1, and Elmo-1 by microRNA-143 and microRNA-365 Promotes the Intracellular Growth of Mycobacterium tuberculosis in Alternatively IL-4/IL-13 Activated Macrophages. Frontiers in Immunology, 2019, 10, 421.	4.8	37
13	Statins: a viable candidate for host-directed therapy against infectious diseases. Nature Reviews Immunology, 2019, 19, 104-117.	22.7	95
14	Batf2 differentially regulates tissue immunopathology in Type 1 and Type 2 diseases. Mucosal Immunology, 2019, 12, 390-402.	6.0	19
15	Transcriptional landscape of Mycobacterium tuberculosis infection in macrophages. Scientific Reports, 2018, 8, 6758.	3.3	92
16	An evaluation of Minor Groove Binders as anti-fungal and anti-mycobacterial therapeutics. European Journal of Medicinal Chemistry, 2017, 136, 561-572.	5.5	15
17	Evaluation of minor groove binders (MGBs) as novel anti-mycobacterial agents and the effect of using non-ionic surfactant vesicles as a delivery system to improve their efficacy. Journal of Antimicrobial Chemotherapy, 2017, 72, 3334-3341.	3.0	18
18	FANTOM5 CAGE profiles of human and mouse samples. Scientific Data, 2017, 4, 170112.	5.3	195

#	Article	IF	CITATIONS
19	IL-4Rα Signaling in Keratinocytes and Early IL-4 Production Are Dispensable for Generating a Curative T Helper 1 Response in Leishmania major-Infected C57BL/6 Mice. Frontiers in Immunology, 2017, 8, 1265.	4.8	12
20	Genome-wide profiling of transcribed enhancers during macrophage activation. Epigenetics and Chromatin, 2017, 10, 50.	3.9	41
21	IRNdb: the database of immunologically relevant non-coding RNAs. Database: the Journal of Biological Databases and Curation, 2016, 2016, baw138.	3.0	12
22	IL-4Rα-Dependent Alternative Activation of Macrophages Is Not Decisive for Mycobacterium tuberculosis Pathology and Bacterial Burden in Mice. PLoS ONE, 2015, 10, e0121070.	2.5	23
23	Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. Science, 2015, 347, 1010-1014.	12.6	517
24	Batf2/Irf1 Induces Inflammatory Responses in Classically Activated Macrophages, Lipopolysaccharides, and Mycobacterial Infection. Journal of Immunology, 2015, 194, 6035-6044.	0.8	83
25	Redefining the transcriptional regulatory dynamics of classically and alternatively activated macrophages by deepCAGE transcriptomics. Nucleic Acids Research, 2015, 43, 6969-6982.	14.5	54
26	Host-directed drug therapy for tuberculosis. Nature Chemical Biology, 2015, 11, 748-751.	8.0	44
27	Targeting Batf2 for infectious diseases and cancer. Oncotarget, 2015, 6, 26575-26582.	1.8	31
28	A promoter-level mammalian expression atlas. Nature, 2014, 507, 462-470.	27.8	1,838
29	Statin Therapy Reduces the Mycobacterium tuberculosis Burden in Human Macrophages and in Mice by Enhancing Autophagy and Phagosome Maturation. Journal of Infectious Diseases, 2014, 209, 754-763.	4.0	245
30	Preclinical efficacy and safety of an anti-IL- $\hat{1}^2$ vaccine for the treatment of type 2 diabetes. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14048.	4.1	47
31	Simvastatin Enhances Protection against Listeria monocytogenes Infection in Mice by Counteracting Listeria-Induced Phagosomal Escape. PLoS ONE, 2013, 8, e75490.	2.5	39
32	The C-type Lectin Receptor CLECSF8 (CLEC4D) Is Expressed by Myeloid Cells and Triggers Cellular Activation through Syk Kinase. Journal of Biological Chemistry, 2012, 287, 25964-25974.	3.4	110
33	Syk Kinase-Coupled C-type Lectin Receptors Engage Protein Kinase C-δ to Elicit Card9 Adaptor-Mediated Innate Immunity. Immunity, 2012, 36, 32-42.	14.3	249
34	Blocking IL- \hat{l}_{\pm} but not IL- \hat{l}_{-}^2 increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine, 2011, 29, 1339-1346.	3.8	53
35	PKCδ regulates ILâ€12p40/p70 production by macrophages and dendritic cells, driving a type 1 healer phenotype in cutaneous leishmaniasis. European Journal of Immunology, 2011, 41, 706-715.	2.9	21
36	The Syk/CARD9-coupled receptor Dectin-1 is not required for host resistance to Mycobacterium tuberculosis in mice. Microbes and Infection, 2011, 13, 198-201.	1.9	61

#	Article	IF	CITATIONS
37	CD28 and IL-4: two heavyweights controlling the balance between immunity and inflammation. Medical Microbiology and Immunology, 2010, 199, 239-246.	4.8	23
38	Limited Role for Lymphotoxin \hat{l}_{\pm} in the Host Immune Response to Mycobacterium tuberculosis. Journal of Immunology, 2010, 185, 4292-4301.	0.8	26
39	The Role of Scavenger Receptor B1 in Infection with Mycobacterium tuberculosis in a Murine Model. PLoS ONE, 2009, 4, e8448.	2.5	64
40	A Virus-Like Particle-Based Vaccine Selectively Targeting Soluble TNF-α Protects from Arthritis without Inducing Reactivation of Latent Tuberculosis. Journal of Immunology, 2007, 178, 7450-7457.	0.8	104
41	Protein kinase C \hat{l} is essential for optimal macrophage-mediated phagosomal containment of <i>i</i> >Listeria monocytogenes <i>i</i> >. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16251-16256.	7.1	35
42	Differential Effects of Total and Partial Neutralization of Tumor Necrosis Factor on Cell-Mediated Immunity to Mycobacterium bovis BCG Infection. Infection and Immunity, 2005, 73, 3668-3676.	2.2	25
43	Contribution of Transmembrane Tumor Necrosis Factor to Host Defense against Mycobacterium bovis Bacillus Calmette-Guerin and Mycobacterium tuberculosis Infections. American Journal of Pathology, 2005, 166, 1109-1120.	3.8	80
44	Circulating concentrations of interleukin-18, interleukin-18 binding protein, and gamma interferon in patients with alcoholic hepatitis. Liver International, 2004, 24, 582-587.	3.9	18
45	Inhibition of inducible nitric oxide synthase protects against liver injury induced by mycobacterial infection and endotoxins. Journal of Hepatology, 2004, 41, 773-781.	3.7	54
46	Both the Fas Ligand and Inducible Nitric Oxide Synthase Are Needed for Control of Parasite Replication within Lesions in Mice Infected with Leishmania major whereas the Contribution of Tumor Necrosis Factor Is Minimal. Infection and Immunity, 2003, 71, 5287-5295.	2.2	42
47	Transmembrane TNF Induces an Efficient Cell-Mediated Immunity and Resistance to <i>Mycobacterium bovis</i> Bacillus Calmette-Guelrin Infection in the Absence of Secreted TNF and Lymphotoxin-α. Journal of Immunology, 2002, 168, 3394-3401.	0.8	107
48	Differential effects of TNF and LT \hat{l}_{\pm} in the host defense againstM. bovis BCG. European Journal of Immunology, 2001, 31, 1935-1943.	2.9	49
49	Lethal Mycobacterium Bovis Bacillus Calmette Guérin Infection in Nitric Oxide Synthase 2-Deficient Mice: Cell-Mediated Immunity Requires Nitric Oxide Synthase 2. Laboratory Investigation, 2000, 80, 1385-1397.	3.7	76
50	A role for lymphotoxin \hat{l}^2 receptor in host defense againstMycobacterium bovis BCG infection. European Journal of Immunology, 1999, 29, 4002-4010.	2.9	40